Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 2011. The document serves as a notification of transactions involving a Person Discharging Managerial Responsibility, specifically regarding changes in interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific insider transaction and does not contain consolidated financial statements or performance metrics.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The only reported activity is the exercise of share options and subsequent sale of shares by a senior executive.
Management Commentary and Risks
The filing details a transaction by Mr. J R Stéphenne on December 2, 2011:
- Exercise of options over 90,000 Ordinary shares granted on December 3, 2002, at a price of £11.79 per share.
- Sale of 90,000 Ordinary shares on the same date at a price of £14.155 per share.
The transaction was notified in accordance with Disclosure Rule 3.1.4R(1)(a). No other risks, contingencies, or unusual items are mentioned.
Investor Verification Points
- Verify the total shareholding of Mr. J R Stéphenne following this transaction.
- Confirm the market price of GSK shares on December 2, 2011, to contextualize the sale price of £14.155.
- Review the company's annual report (Form 20-F) for comprehensive financial data, as this filing contains none.